Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesAromatase inhibition in male breast cancer patients: Biological and clinical implications
Annals of Oncology, 10/29/09
Doyen J et al. – The role of aromatase inhibitors (AIs) and their impact on estradiol (E2) levels remain unknown in male breast cancer (MBC) patients. AIs are active in MBC patients. This activity is correlated with a significant reduction in E2 levels. Secondary resistance is in part related to a deleterious feedback loop resulting in a significant increase in substrate for aromatization.
Methods- MBC patients with metastatic disease and those treated with AIs selected from breast cancer database of Centre Antoine-Lacassagne
- Sex hormone levels retrospectively assessed on serum samples from our institutional serum bank
- 15 patients
- 2 patients (13%) had complete response, 4 patients (27%) had partial response, 2 patients (13%) had stable disease and 7 patients (47%) had progressive disease
- Median PFS and overall survival were 4.4 months [95% confidence interval (CI) 0.1–8.6] and 33 months (95% CI 18.4–47.6), respectively
- All assessable patients (n = 6) had E2 levels less than lower limit of assay during AI treatment
- 3 had partial response, 1 had stable disease and 2 had progressive disease
- Large increase in follicle-stimulating hormone, LH and E2 levels observed in 1 responding patient at progression
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤ 1 cm) invasive breast cancer: Who might be possible candidates for adjuvant treatment?
Breast Cancer Research and Treatment, 12/09/09
Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes
Breast Cancer Research, 12/09/09
Prognostic significance of Dicer expression in ovarian cancer - link to global microRNA changes and oestrogen receptor expression
The Journal of Pathology, 12/09/09
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤ 1 cm) invasive breast cancer: Who might be possible candidates for adjuvant treatment?
Breast Cancer Research and Treatment, 12/09/09
Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab
Clinical Cancer Research, 12/09/09
Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes
Breast Cancer Research, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor